CPE Capital (CPEC) has sold Cell Care to Generate Life Sciences, the world’s largest provider of newborn stem cell services and reproductive tissue banks.
During CPEC’s 2.5 year investment, Cell Care experienced consistent growth in EBITDA, including through the COVID-19 pandemic. The growth in CPEC’s equity value came from the successful implementation of several initiatives, including:
- Entering into new hospital partnership agreements, particularly in Australia;
- Introducing new online marketing channels and increasing presence on social media;
- Updating and optimising the pricing structure in Canada; and
- Developing a number of other future growth initiatives including: the public bank partnership, entry into the NZ market and a new placental storage business.
This exit continues the CPEC 8 Fund’s strong momentum, following April’s sale of Gourmet Food Holdings.